CD38 and Miyoshi myopathy: For instance, anti-CD38 monoclonal antibodies, such as daratumumab, as well as other novel MM therapeutics—including bortezomib, lenalidomide, and dexamethasone—have demonstrated prolonged median progression-free survival of 41 months compared to the 8.5 months for control cohorts39.